Lipid Profiles

2

Review clinical trials related to Lipid Profiles. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)

Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic splenectomy is commonly used to treat splenomegaly and hypersplenism in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing laparoscopic splenectomy to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether laparoscopic splenectomy can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.

Participants needed: 30
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Northern Jiangsu People's HospitalUpdated: May 14, 2026Locations: 1Duration: 2 Years
Eligibility criteria

Age 18-80 years, male or female [+5]

Child-Pugh Class C liver cirrhosis [+8]

Status: Not yet recruiting

Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)

Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing LSD to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether LSD can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.

Participants needed: 30
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Northern Jiangsu People's HospitalUpdated: May 14, 2026Locations: 1Duration: 2 Years
Eligibility criteria

Age 18-80 years, male or female [+6]

Child-Pugh Class C liver cirrhosis [+7]